A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience

AIDS

Volumn 13, Issue 17, 1999, Pages 2411-2420

  Haubrich, Richard ^a,k   Thompson, Melanie ^b   Schooley, Robert ^c   Lang, William ^d   Stein, Allan ^e   Sereni, Daniel ^f   Van Der Ende, Marchina E ^l   Antunes, Francisco ^g   Richman, Douglas ^a,h   Pagano, Grace ^l   Kahl, Lesley ⁱ   Fetter, Anny ⁱ   Brown, David J ⁱ   Clumeck, Nathan ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AIDS Research Consortium of Atlanta   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d ViRx Inc   (United States)

^e Community AIDS Resource Inc ^*  (United States)

^f SAINT LOUIS HOSPITAL   (France)

^g HOSPITAL DE SANTA MARIA   (Portugal)

^h VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l NONE

more..

Author keywords

Amprenavir; Antiretroviral therapy; Lamivudine; Protease inhibitor; Zidovudine

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; PLACEBO; PROTEINASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EUROPE; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; SLEEP DISORDER; TASTE DISORDER; UNITED STATES; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; CARBAMATES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NAUSEA; RNA, VIRAL; SAFETY; SULFONAMIDES; TIME FACTORS; VIREMIA; ZIDOVUDINE;

EID: 0032777353     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00013     Document Type: Article

References (47)

1. 1. Haubrich R, Lalezari J, Follansbee FE, et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998, 3:33-42.
2. 2. Hammer SM, Squires KF, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
3. 3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
4. 4. Centers for Disease Control and Prevention. Update: Trends in AIDS Incidence - United States, 1996. MMWR 1997, 46:861-864.
5. 5. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic infections. Lancet 1998, 351:228-230.
6. 6. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 1998, 280:78-86.
7. 7. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
8. 8. Johnson M, Nelson M, Peters B, et al. A comparison of BID and TID dosing of nelfinavir when given in combination with stavudine (d4T) and lamivudine (3TC) for up to 48 weeks. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract I-216].
9. 9. Farlhing C, Norris D, Slater L, et al. Fortovase™ (SQV) SGC bid regimens in combination with two nucleosides or nelfinavir (NFV) plus one nucleoside in HIV-1 infected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract I-105].
10. 10. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.
11. 11. Paterson DL, Swindels S, Mohr JA, et al. Adherence with protease inhibitor therapy for human immunodeficiency virus infection. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract I-172].
12. 12. Haubrich R, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999, 13:1099-1107.
13. 13. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia [letter]. Lancet 1997, 350:713-714.
14. 14. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet 1998, 351:1736.
15. 15. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
16. 16. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
17. 17. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society USA Panel. J Am Med Assoc 1998, 279:1984-1991.
18. 18. Haubrich R, Currier J, Forthal D, et al. Low rate of maximal suppression of HIV-1 RNA in a trial of RNA monitoring in clinical practice. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September October 1997 [abstract I-128b].
19. 19. Adkins JC, Faulds D. Amprenavir. Drugs 1998, 55:837-842.
20. 20. St Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents, Antiviral Res 1996, 29:53-56.
21. 21. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995, 69:5228-5235.
22. 22. Drusano GL, D'Argenio DZ, Symonds W, et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agent Chemother 1998, 42:2153-2159.
23. 23. Sadler BM, Elkins M, Hanson C, et al. The safety and pharmacokinetics of 141W94: an HIV protease inhibitor. Fifth European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen, Denmark. September 1995 [abstract 564].
24. 24. Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS. Safety and pharmacokinetics of amprenavir (141W94), an HIV-1 protease inhibitor, following oral administration of single doses in HIV-infected adults. Antimicrob Agents Chemother, 1999, 43:1686-1692.
25. 25. Livingston DJ, Pazhanisamy S, Porter DJT, et al. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995, 172:1238-1245.
26. 26. Sadler BM, Rawls C, Millard J, Hanson C, Dowd P. Pharmacokinetics of 141W94 after multiple dosing in patients with HIV infection: a preliminary report. Antiviral Res 1996, 30:A42
27. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997, 175:1063-1070.
28. 28. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions, J Pharmaceut Sci 1998, 87:803-807.
29. 29. Woolley J, Studenberg S, Boehlert C, et al. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September October 1997 [abstract A-60].
30. 30. Polk R, Israel DS, Pastor A, et al. Effects of 141W94 and clarithromycin (CLRV) on P450 (CYP) 3Z4 activity as measured by the erythromycin breath test (ERMBT). Clin Infect Dis 1997, 25:399.
31. 31. Polk RF, Israel DS, Patron R, et al. Pharmacokinetic (PK) inter-action between 141W94 and rifabutin (RFB) and rifampin (RFP) after multiple dose administration. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 340].
32. 32. Polk RF, Israel DS, Pastor A, et al. Effects of ketoconazole (KCZ) and 141W94 on P450 (CYP)3A4 activity measured by the erythromycin breath test (ERMBT). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 341].
33. 33. Sadler B, Gillotin C, Chittick GE, et al. Pharmacokinetic drug interactions with amprenavir. XII International Conference on AIDS, Geneva, June 1998 [abstract 12389].
34. 34. Ravilch JR, Bryant BJ, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the anti-retroviral 1592 in humans. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998 [abstract 634].
35. 35. Sadler BM, Wald J, Lou Y, et al. The single-dose pharmacokinetics of 141W94, zidovudine and lamivudine when administered alone and in two-and three-drug combinations. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 257].
36. 36. Lenhard J, Weiel J, Paulik M, et al. Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retinoid effects in vitro. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January-February 1999 [abstract 665].
37. 37. Lenhard J, Weiel J, Paulik M, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January-February 1999 [abstract 666].
38. 30. Pazhanisamy S, Partaledis JA, Rao BG, et al. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv Exp Med Biol 1998, 436:75-83.
39. 39. Boden D, Markowitz M, Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agent Chemother 1998, 42:2775 2783.
40. 40. De Pasquale MP, Murphy R, Gulick R, et al. Mutations selected in HIV plasma RNA during 141W94 therapy. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 406a].
41. 41. Tisdale M, Myers RE, Ait-Khaled M, et al. HIV drug resistance analysis during clinical studies with the protease inhibitor amprenavir. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago. January-February 1999 (abstract 118].
42. 42. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-13.
43. 43. Tashima K, Staszewski S, Stryker R, et al. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 48 weeks (Study DMP 266-006). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract LB16].
44. 44. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998, 47(RR-5):1-79. [December 1, 1998 update available on the internet at www.HIVATIS.org]
45. 45. Gazzard B, Moyle G, 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998, 352:314-316.
46. 46. Pedneault L, Fetter A, Hanson C, et al. Amprenavir (141W94, APV USAN approved): review of overall safety profile. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 386].
47. 47. Murphy RL, Gulick R, Smeaton L, et al. Treatment with indinavir, nevirapine, stavudine, and 3TC following therapy with an amprenavir-containing regimen: ACTG 373. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, November 1998 [abstract OP2.4].